Trials / Completed
CompletedNCT02151760
Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
- Sex
- Male
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study is being done to determine the safety, biodistribution, and radiation dosimetry of 18F-DCFPyL, and to detect prostate cancer by visual analysis.
Detailed description
To assess the hypothesis that this new 2nd generation positron emission tomography (PET) radiopharmaceutical, 18F-DCFPyL, may possess pharmacokinetic and pharmacodynamic properties that will represent an advance in imaging metastatic prostate cancer in ten patients diagnosed with metastatic prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-DCFPyL |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2020-04-01
- Completion
- 2020-04-01
- First posted
- 2014-05-30
- Last updated
- 2020-05-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02151760. Inclusion in this directory is not an endorsement.